Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.2% – Still a Buy?

Vera Therapeutics, Inc. (NASDAQ:VERA)’s stock price traded up 6.2% on Monday . The stock traded as high as $34.18 and last traded at $34.2870. Approximately 290,245 shares were traded during trading, a decline of 80% from the average session volume of 1,461,276 shares. The stock had previously closed at $32.28.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wedbush reaffirmed a “neutral” rating and issued a $34.00 target price on shares of Vera Therapeutics in a research note on Monday, August 17th. HC Wainwright dropped their price target on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Raymond James Financial restated a “strong-buy” rating and issued a $84.00 price objective on shares of Vera Therapeutics in a report on Tuesday, August 11th. TD Cowen increased their price objective on shares of Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $81.15.

Vera Therapeutics Stock Up 5.6%

The business has a fifty day moving average of $36.32 and a 200 day moving average of $37.99. The firm has a market cap of $2.46 billion, a P/E ratio of -5.82 and a beta of 0.92. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the firm posted ($1.20) EPS. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -6.43 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer directly owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several large investors have recently bought and sold shares of VERA. Price T Rowe Associates Inc. MD raised its holdings in Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Deerfield Management Company L.P. increased its position in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after buying an additional 293,040 shares in the last quarter. Vanguard Group Inc. raised its stake in Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares during the period. Vestal Point Capital LP raised its stake in Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the period. Finally, Eversept Partners LP raised its stake in Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after buying an additional 264,468 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.